Recombinant Mycobacterium smegmatis vaccine expressing HBHA-IL-12 fusion protein

Abstract

The invention discloses a recombinant Mycobacterium smegmatis vaccine expressing an HBHA-IL-12 fusion protein. The vaccine takes Mycobacterium smegmatis as a host cell, and an exogenous expression vector for transfecting the host cell contains HBHA-IL-12 gene segments. The recombinant Mycobacterium smegmatis vaccine can continuously express the bioactive HBHA-IL-12 fusion protein, and the induced IFN-gamma can effectively remove the infected MTB in a mouse. The vaccine combines the advantages of a target antigen and the live vector, and can be used for treating MTB infection.

Description

technical field [0001] The invention belongs to the technical field of medicine and biology, and relates to a recombinant mycobacterium smegmatis (rM.S) vaccine, in particular to a recombinant mycobacterium smegmatis vaccine expressing HBHA-IL-12 fusion protein. Background technique [0002] 1. A therapeutic vaccine for TB is urgently needed [0003] At present, about 1 / 3 of the world's population is in a state of persistent infection with Mycobacterium tuberculosis (M.tuberculosis, MTB), and 5% to 10% of infected people may eventually develop into active tuberculosis (TB) and become MTB. important source of infection. Chemotherapy is the basic treatment for tuberculosis. Although some active TB patients can be cured by this method, due to the long treatment time and serious side effects, the patient's compliance is poor, and it is easy to lead to the occurrence of drug resistance and persistent infection. Therefore, there is an urgent need to develop drugs or therapeutic ...

AI Technical Summary

Problems solved by technology

DNA vaccine is currently the most researched therapeutic vaccine, but its main problems are: the encoded antigen is relatively single, the immune response induced is very different from the natural infection process of MTB, multiple immunizations are required, and immune tolerance is easily induced and the production of autoantibodies; the residence time of subunit vaccines in the body is short, and it is difficult to trigger long-term effective immune responses; while live vector vaccines are superior to other genetically engineered vaccines in stimulating the body to produce protective immune responses, and are the focus of therapeutic vaccine research. an important direction

[0014] Although the above-mentioned protective antigens can induce effective cellular immune responses after immunization alone, their therapeutic effects on MTB infection still need to be further improved

Images